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tive patients based on ALT activity is controversial and current
guidelines favor liver biopsy in HBeAg-negative cases with nor-
mal ALT and HBV DNA >2000 IU/ml. We systematically reviewed
all the available histological data on HBeAg-negative patients
with persistently normal ALT (PNALT) to determine the preva-
lence of signiﬁcant liver disease and its associating factors.
Methods: Literature search to identify studies with adult HBeAg-
negative patients who had PNALT as deﬁned by the authors, a
minimum follow-up of 1 year and histological data. Traditional
cut-off values of normal ALT were used in all studies. The deﬁni-
tions of PNALT were considered as acceptable or good if there
were P3 ALT determinations at unspeciﬁed intervals during 6–
12 months or predeﬁned intervals during P12-month periods,
respectively.
Results: Six studies including 335 patients met our inclusion cri-
teria. Of these, four studies with 246 patients had good or accept-
able deﬁnitions of PNALT. In the latter four studies, more than
minimal (usually mild) necro-inﬂammatory activity was
observed in 10% and more than mild ﬁbrosis in 8% of all patients
(moderate ﬁbrosis: 7%, severe ﬁbrosis: 1%, cirrhosis: 0%), and in
3% and 5% of patients with HBV DNA 620,000 IU/ml, respectively.
Conclusions: Histologically signiﬁcant liver disease is rare in
HBeAg-negative patients with PNALT based on stringent criteria
and serum HBV DNA 620,000 IU/ml. Such cases can be consid-
ered as true inactive HBV carriers, who require neither liver
biopsy nor immediate therapy but continued follow-up.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Journal of Hepatology 20
Keywords: Hepatitis B; Inactive carrier; ALT; HBV DNA; Liver biopsy.
Received 22 July 2011; received in revised form 24 November 2011; accepted 30
November 2011
*Corresponding author. Address: 2nd Department of Internal Medicine, Athens
University Medical School, ‘‘Hippokration’’ General Hospital of Athens, 114 Vas.
Sophias Ave., 115 27 Athens, Greece. Tel.: +30 210 7774742; fax: +30 210
7706871.
E-mail address: gepapath@med.uoa.gr (G.V. Papatheodoridis).
Abbreviations: HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBeAg,
hepatitis B e antigen; ALT, alanine aminotransferase; PNALT, persistently normal
ALT; PCR, polymerase chain reaction.Worldwide, approximately 400million people have chronic infec-
tion with hepatitis B virus (HBV), which usually runs a variable
course lasting for decades and often the entire life, with outcomes
ranging from asymptomatic carrier state to cirrhosis, liver failure,
and hepatocellular carcinoma (HCC) [1–4]. The natural history of
chronicHBV infectionhasbeendivided intodifferent phases, based
onhepatitis B e antigen (HBeAg) status, serumHBVDNA levels, and
alanine aminotransferase (ALT) activity [1,2].
In the HBeAg-negative phases, the majority of patients remain
in an inactive, low-replicative state (inactive HBV carrier state).
Inactive carriers are negative for HBeAg; and have persistently
normal ALT (PNALT), low or undetectable serum HBV DNA levels,
minimal or no necroinﬂammation and generally minimal to mild
ﬁbrosis on liver biopsy. A proportion of HBeAg-negative patients,
however, may progress to an immune active phase (HBeAg-neg-
ative chronic hepatitis B) with persistently or transiently elevated
ALT and high serum HBV DNA levels [1–3].
Theoretically, serum levels of ALT, an enzyme that is released
from hepatocytes during liver injury, should reﬂect the degree of
liver damage [5]. However, several reports have suggested that
patients with chronic HBV infection who are HBeAg negative
and have normal ALT may have high serum HBV DNA levels
and signiﬁcant histological liver damage [6,7]. Such cases have
created debates and clinical dilemmas regarding the adequacy
of monitoring HBeAg-negative patients based on ALT activity
only, the need for liver biopsy, and the indication for treatment
[3]. We systematically reviewed all the available histological data
on HBeAg-negative patients with PNALT focusing on those with
serum HBV DNA below 20,000 IU/ml to determine the prevalence
of signiﬁcant liver disease in this setting and its associating
factors.Search strategy and selection criteria
Medline/Pubmed from January 2000 to December 2010 was
searched to identify all medical literature included under the
search text terms ‘‘normal ALT’’ or ‘‘HBV DNA’’, and ‘‘carriers’’.
In addition, a manual search of all relevant review articles and
the references of the retrieved original studies was performed.12 vol. 57 j 196–202
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All studies published in English as full papers were included, if
they fulﬁlled all of the following criteria: (1) adult patients with
HBeAg-negative chronic HBV infection and PNALT as deﬁned by
the authors, (2) minimum mean or median follow-up of 1 year,
(3) data on liver histology in relation to ALT and serum HBV
DNA levels in a minimum of 20 HBeAg-negative patients with
PNALT. Patients with co-infections with other hepatitis viruses
and/or human immunodeﬁciency virus, other causes of liver dis-
ease, or antiviral or immunosuppressive therapy in the past were
excluded.
Literature search was performed by two independent review-
ers (GVP, SM), who determined which studies might meet the
inclusion and exclusion criteria. Two lists of selected papers were
compared for concordance. The same two independent reviewers
extracted data from the selected papers using a standardized
form. Two data summary tables were prepared and compared
for concordance. Discrepancies were resolved during a joint
review of the papers by the two reviewers.Studies and patients characteristics
There were 1015 manuscripts initially identiﬁed from the litera-
ture search. Of these, only ﬁve studies were included and 1010
were excluded (978 after reviewing the abstract and 32 after
reading the full manuscript). A manual search of the references
of the 37 manuscripts reviewed found 12 additional potentially
eligible studies; one of them was found to fulﬁll the inclusion cri-
teria. Thus, six studies were ﬁnally included [7–12].
In total, there were 451 HBeAg-negative patients with PNALT
(from 25 to 116 patients in each study, but only 335 of them had
undergone liver biopsies (from 25 to 95 patients in each study).
Their mean or median age ranged from 34 to 43 years, and the
majority of patients were males. The racial origin of patients
varied among the studies, with two studies including patientsTable 1. Main characteristics of studies with histological data in patients with HBeAg-
(PNALT).
Author, year
[Ref.]
Study 
design
Primary 
study question
Martinot-Peignoux et al., 2002 
[8]
RE-PR 
cohort
Correlation of HBV DNA level
their changes with liver histolo
Ikeda et al., 2006 
[9]
RE 
cohort
Incidence of advanced liver di
in HBeAg-negative patients w
normal ALT
Lai et al., 2007 
[10]
RE 
cohort patients with PNALT and HBV
>10,000 copies/ml
Kumar et al., 2008 
[7]
PR 
cohort
Histological lesions in patients
PNALT and HBV DNA cut-off 
as predictors of histology
Zacharakis et al., 2008 
[11]
PR 
cohort
The role of HBV DNA levels in
long-term outcome of chronic 
infection
Papatheodoridis et al., 2008 
[12]
RE 
cohort
Severity of histological lesions
relation to ALT and HBV DNA
levels
Incidence of significant histolo
RE, retrospective; PR, prospective; M/F, males/females; C, Caucasians, A; Asians; B, Blac
⁄Age as mean ± standard deviation or median (range).
#Only 58 patients underwent liver biopsy.
Journal of Hepatology 201of several races [8,10], two studies included exclusively Cauca-
sian patients [11,12], one study had exclusively Japanese patients
[9] and another study had exclusively patients from India [7].
Alcohol abuse was reported by almost no patient in ﬁve studies
[7,8,10–12] and by 16% of patients in one study [9] (Table 1).
The deﬁnitions of alcohol abuse varied widely among studies
ranging from >20 g/day [11], >30/20 g/day in males/females dur-
ing the previous year [12], >50 g/day for P5 years [10], >500 kg
in total [9] to unspeciﬁed [7,8].Deﬁnition of PNALT
The deﬁnition of PNALT varied widely among the six studies. The
traditional upper limit of normal was used (40 IU/L in four and
50 IU/L in one study and unspeciﬁed in the remaining study),
and the minimum number of ALT determinations prior to liver
biopsy varied from 2 to 5. The frequency of initial ALT determina-
tions was speciﬁcally deﬁned in only one study [12] and the min-
imum duration of monitoring prior to biopsy varied from 0 to
12 months. Liver biopsies were reported to be performed at pre-
sentation in one study [11] and after a minimum follow-up of 2, 6
and 12 months in one [9], two [8,10] and two studies [7,12],
respectively. There was less variation in the frequency of ALT
determinations after the ﬁrst year of follow-up (every 6 months
in three studies [8,11,12], every 1–3 months in one study [9]
and not reported in two studies [7,10]), but the duration of fol-
low-up differed substantially among studies ranging from 2
to >48 months (Table 2). In this review, deﬁnitions of PNALT were
considered to be poor if they were based on a minimum of two
ALT determinations, acceptable if they were based on a minimum
of three ALT determinations at unspeciﬁed intervals during a per-
iod of 6–12 months and good if they were based on a minimum of
three ALT determinations at predeﬁned intervals (at least 2
months apart) over a minimum observation period of 12 months.negative chronic hepatitis B virus (HBV) infection and persistently normal ALT
Patients,
n
Age*, 
yr
Gender, 
M/F
Race,
C/A/B
Alcohol 
abuse, n
s and 
gy
85 (58#) 34 ± 11 46/39 45/12/28 0
sease 
ith 
95 39 (18-67) 75/20 Japanese: 95 15
 DNA 
25 43 10/15 2/18/4 1
 with 
levels 
116 (58#) 35 ± 15 79/37 India: 116 0
 the 
HBV 
95 36 (20-45) n.a. 95/0/0 0
 in 
 
35 43 ± 13 22/13 35/0/0 0
gy in
ks; n.a., not available.
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Serum HBV DNA levels
Serum HBV DNA levels were determined once for each patient,
usually at baseline, in three studies [7,10–12] and more than
once for each patient in the remaining three studies [8,9,11].
Only the serum HBV DNA determinations closest to the liver
biopsy were taken into account in our review. Serum HBV
DNA levels were determined by Amplicor HBV Monitor poly-
merase chain reaction (PCR) assay with lower limit of detection
of approximately 40–80 IU/ml in four studies [8,9,11,12] and by
multiple assays with varying sensitivity in two studies [7,10].
Patients with serum HBV DNA above 2000 IU/ml were included
in one study [10], between 2000 and 20,000 IU/ml in another
study [12] and varying serum HBV DNA levels in the remaining
four studies [7–9,11]. The median serum HBV DNA level ranged
from 260 to 5084 IU/ml in ﬁve studies [7–9,11,12]; only the
mean serum HBV DNA level (39,905 IU/ml) was reported in
one study [10]. The maximum serum HBV DNA level ranged
from 3800 to more than 300,000,000 IU/ml. Serum HBV DNA
levels above 20,000 IU/ml were detected in none (0/95 and 0/
35) of the patients in two studies [11,12], in only 2% (2/85)
of patients in one study [8] and in 29–50% of patients (28/95
and 29/58) in two additional studies which provided such data
[7,9] (Table 2).Liver histology
Liver biopsies were evaluated by a single pathologist in three
studies [8,11,12] and by two pathologists in two studies [7,9].
This information was not provided in one study [10]. The pathol-
ogists were reported to be blinded to clinical and laboratory data
in all three studies providing such information [7,11,12]. The
interval between the initial presentation and the liver biopsy ran-
ged from 0 to >12 months. Different histological classiﬁcation
systems were used for grading of inﬂammation and staging of
ﬁbrosis (Table 3).
The mean or median inﬂammation grade and ﬁbrosis stage
were within the range of minimal to mild severity in all ﬁve
studies, which reported such data [7,8,10–12]. However, there
was wide variation in the proportion of patients with active his-
tological lesions among the ﬁve studies providing such informa-
tion [7–9,11,12]. In three studies from Europe [8,11,12], 99.5%
(187/188) of patients were found to have minimal (grade 0–4
of 18 in the Ishak or grade 0 of 4 in the Scheuer classiﬁcation
system) and only one (0.5%) patient had mild necroinﬂammato-
ry activity (grade 5 of 18 in the Ishak classiﬁcation system),
while no or mild ﬁbrosis (stage 0–1/2 of 6 in the Ishak or stage
0–1 of 4 in the Scheuer classiﬁcation system) was present in
96% (177/188) and at least moderate ﬁbrosis (stage P2/3 of 6
in the Ishak classiﬁcation system) in only 4% (11/188) of
patients. The diagnosis of at least moderate ﬁbrosis was based
on Ishak stage P2 in one [12] and Ishak P3 in another study
[8]. Fibrosis staging P3 was present in only 5 (3%) of these
188 patients (4 with staging score of 3, 1 with staging score
of 4, none with cirrhosis (staging score of 5–6)) and it was
always accompanied by minimal necroinﬂammatory activity
(grade 1–4 of 18 in the Ishak classiﬁcation system) [8,11,12].
These three studies had good (n = 2) [11,12] or acceptable
(n = 1) [8] deﬁnitions of PNALT activity, ALT determinations198 Journal of Hepatology 201every 6 months after the ﬁrst year of follow-up, and included
mainly but not exclusively Caucasian patients. Serum HBV
DNA levels were below 20,000 IU/ml in 99% (186/188) of the
patients in these three studies.
In contrast to the above studies, in two studies from Asia
(one from Japan [9] and one from India [7]), at least mild necr-
oinﬂammatory activity (HAI score P4 of 18 in the Knodell or
Desmet classiﬁcation system) was reported to be present in
81% (77/95) and 40% of cases (23/58) and at least moderate
ﬁbrosis (stage P2 of 4 in the Knodell or Desmet classiﬁcation
system) in 35% (33/95) and 14% (8/58) of patients, respectively.
In the study from the USA with 72% Asian patients [10], the
reported ranges of grading and staging scores revealed that
cases of more than mild necroinﬂammatory activity and of
advanced ﬁbrosis and even cirrhosis were detected although
the exact proportions of patients with advanced histological
lesions could not be determined.
Besides the patients’ origin, there were additional important
differences between the three European and the other three stud-
ies. The Japanese study [9], which reported the highest propor-
tion of patients with active histological lesions, had poor
deﬁnition of PNALT activity prior to biopsy (ALT <50 IU/L in P2
determinations P2 months apart). Careful ALT follow-up after
the biopsy showed that 55% (52/95) of the patients had abnormal
ALT. In fact, 52% (49/95) of the patients in that study were
reported to have a history of ALT elevation (n = 41) or evidence
of advanced liver disease on ultrasonography or blood tests
(n = 8) and would not meet the standard deﬁnition of inactive
HBV carriers. In that same study [9], the highest prevalence of
alcohol abuse was reported (16%) and 29% of patients had base-
line serum HBV DNA >20,000 IU/ml but histological data accord-
ing to viremia levels were not provided. In the study from India
[7], there was an acceptable deﬁnition of PNALT (ALT <40 IU/L
inP3 determinations within 12 months, but at unspeciﬁed inter-
vals) and no deﬁned post-biopsy ALT follow-up. In addition, this
study included the highest proportion of patients with baseline
serum HBV DNA >20,000 IU/ml (29/58 or 50%) and very few
patients with serum HBV DNA <2000 IU/ml (9/58 or 16%). Vire-
mia levels were found to be signiﬁcantly related to the presence
of active histological lesions, with at least mild necroinﬂammato-
ry activity detected in 59% (17/29) of patients with serum HBV
DNA >20,000 IU/ml and in 15% (3/20) of those with serum HBV
DNA between 2000 and 20,000 IU/ml (p = 0.003) [7]. In the US
study, there were both poor PNALT deﬁnition and undeﬁned
post-biopsy ALT follow-up. In addition, patients with clinical evi-
dence of cirrhosis were included [10]. Of greater importance is
that only patients with baseline serum HBV DNA >2000 IU/ml
were included [10].
When the analysis was limited to the 215 patients with serum
HBV DNA 620,000 IU/ml from the four studies with good or
acceptable deﬁnitions of PNALT [7,8,11,12], more than minimal
(always mild) necroinﬂammatory activity was reported to be
present in only 7 (3%) and more than mild ﬁbrosis in only 10
(5%) patients (moderate ﬁbrosis: 9, severe ﬁbrosis: 1, cirrhosis:
0). The patients with more than mild ﬁbrosis all had minimal
necroinﬂammatory activity. More than minimal necroinﬂamma-
tory activity was present in 5 (7%) and more than mild ﬁbrosis
in 7 (10%) out of 73 patients with serum HBV DNA between
2000 and 20,000 IU/ml and in 2 (1.4%) and 1 (0.7%) of 142
patients with serum HBV DNA <2000 IU/ml.2 vol. 57 j 196–202
Table 2. ALT and HBV DNA characteristics of patients with HBeAg-negative chronic hepatitis B virus infection and persistently normal ALT (PNALT).
ALT determinations Serum HBV DNA at baseline
Author, 
year
[Ref.]
F-UP, 
mo PNALT
Within 1st yr of F-UP After 1st yr Median* Patients 
with HBV 
DNA
Method
n Frequency Frequency IU/ml <2000/
2000-20,000/
>20,000
Martinot-Peignoux et al., 
2002 
[8]
38 ± 31 
(6-132)
≤40 IU/L in 3 
determinations 
within 6 mo
4 3 determinations 
within 6 mo
then every 6 mo
Every 6 mo 260 
(<40-35,800)
69/14/2 Amplicor 
HBV 
monitor
Ikeda et al., 
2006 
[9]
≥2 ≤50 IU/L in ≥2 
determinations 
≥2 mo apart
n.a. After biopsy: 
every 1-3 mo
Every 1-3 mo 5023 
(<80-
7962,143)
33/34/28 Amplicor 
HBV 
monitor
Lai et al., 
2007 
[10]
≥6 ≤40 IU/L in ≥2 
determinations 
≥6 mo apart
n.a. n.a. n.a. mean: 
39,905
Unknown Non-PCR/
PCR assays
Kumar et al., 
2008 
[7]
≥12 ≤40 IU/L in ≥3 
determinations 
within 12 mo 
3 n.a. n.a. 3990 
(<130-
316,978,638)
9/20/29# Digene/PCR 
Zacharakis et al., 
2008
[11]
≥48 ≤40 IU/L in ≥3 
determinations 
every 6 mo within 
3 Every 6 mo Every 6 mo 520 
(84-3800)
91/4/0 Amplicor 
HBV 
monitor
Papatheodoridis et al., 
2008 
[12]
≥12 40 IU/L in ≥5 
determinations 
every 3 mo within 
5 Every 3 mo Every 6 mo 5084 
(2000-
18,700)
0/35/0 Amplicor 
HBV 
monitor
Definition of
first ≥12 mo
first 12 mo
assay
F-UP, follow-up; mo, months; n.a., not available; PCR, polymerase chain reaction.
⁄Median (range) values are expressed in IU/ml (values given as copies/ml were converted to IU/ml by dividing by a factor of 5).
#Of the 58 patients who underwent liver biopsy.
Table 3. Histological characteristics of patients with HBeAg-negative chronic hepatitis B virus infection and persistently normal ALT.
Author, year
[Ref.]
Single 
pathologist
Blind 
evaluation
Biopsy 
timing#, mo
Scoring 
system
Grading Staging Activity, 
min/mild/≥mod.
Fibrosis,
no-mild/≥mod.
Martinot-Peignoux et al., 2002 
[8]
Yes Unknown Unknown Ishak 2 ± 1 
(0-4)
1.4 ± 0.9 
(0-4)
58/0/0 53!/5
Ikeda et al., 2006 
[9]
No (2) Unknown ≥2 Desmet - - 18/72/5 62/33
Lai et al., 2007 
[10]
Unknown Unknown* ≥6 Metavir 1.4 
(0-3)
0.8
(0-4)
Unknown Unknown
Kumar et al., 2008 
[7]
No (2) Yes ≥12 Knodell 3 
(1-10)
1 
(0-3)
35/23¶ 50/8
Zacharakis et al., 2008 
[11]
Yes Yes 0 Scheuer 0 0 
(0-1)
95/0/0 95/0
Papatheodoridis et al., 2008 
[12]
Yes Yes ≥12 Ishak 2.9 ± 0.9
(0-5)
1.0 ± 0.6 
(0-2)
34/1/0 29/6
min, minimal; mod, moderate.
⁄Inclusion of cases with clinical cirrhosis as well.
#Mean interval from baseline to liver biopsy.
–Twenty-three patients had at least mild necroinﬂammatory activity (HAI >3).
!Fifty-three patients had ﬁbrosis score 62.
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This systematic review was conducted to ascertain the preva-
lence of histologically signiﬁcant liver disease in HBeAg-negative
patients with PNALT. Our ﬁndings showed a wide range in prev-
alence of signiﬁcant liver disease among studies that was pre-
dominantly related to the quality of the deﬁnition of PNALTJournal of Hepatology 201and the serum HBV DNA levels. Thus, only 10% of patients had
at least mild inﬂammatory activity and 8% had at least moderate
ﬁbrosis in the four studies with good or acceptable deﬁnitions of
PNALT [7,8,11,12] compared to 81% and 35% of patients, respec-
tively, in one study with poor criteria for PNALT [9].
Although the optimal deﬁnition of PNALT has not been estab-
lished, the ﬂuctuating nature of chronic HBV infection reasonably2 vol. 57 j 196–202 199
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justiﬁes serial ALT determinations with a minimum of 4–5 read-
ings 3–4 months apart within the ﬁrst year of presentation,
before determining whether an HBeAg-negative patient truly
has PNALT. An initial follow-up of at least 1 year is supported
by the ﬁnding of mild histological lesions in HBeAg-negative
patients with truly PNALT during the ﬁrst year [12,13]. Since
the risk of developing abnormal ALT in HBeAg-negative patients
with normal baseline ALT has been reported to be higher during
the ﬁrst year (15–20%) [12,14] and declines after 3 years of fol-
low-up [9,14,15], frequent monitoring during the ﬁrst 1–3 years
is critical in determining whether a patient has PNALT.
Besides the frequency of determinations and duration of fol-
low-up, deﬁnition of PNALT should include standardized criteria
for the upper limit of normal (ULN) of ALT. Some investigators
have suggested that lower cut-offs than the traditional values
deﬁned by most diagnostic laboratories (around 40 IU/L) should
be used. These suggestions were derived from studies based on
single ALT values in Italian blood donors [16], the associations
between normal ALT and increased rates of liver related deaths
in Koreans applying for life insurance [17], and high serum HBV
DNA levels or increased risks of complications of liver diseaseHBeAg-negative patient with n
ALT every 3-4 mo for 
+ serum HBV DNA de
ALT >ULN and/or
HBV DNA >20,000 IU/ml
Liver biopsy
Persistently ALT <
HBV DNA 2000-20
ALT <ULN a
HBV DNA 2000-20
ALT every 6 
HBV DNA every 
transient elastograph
ALT every 3-4
HBV DNA every 
transient elastograph
for two more y
Fig. 1. Clinical algorithm for the optimal follow-up and management of patients with
(ALT) activity at baseline. All patients should have ALT and HBV DNAmonitoring every 3
DNA <2000 IU/ml during the ﬁrst year may be monitored with ALT every 6 months.
frequency of HBV DNA monitoring is unclear. Patients with ALT persistently below the up
should undergo transient elastography and continue every 3–4 months ALT and annual H
because of a higher risk of exacerbations during the ﬁrst 3 years, and then ALT every 6 mo
abnormal ALT, HBV DNA >20,000 IU/ml and/or liver stiffness >9 kPa should be considere
needs further evaluation. All patients, including those with persistently normal ALT and
200 Journal of Hepatology 201in patients with chronic HBV infection [6,18]. However, several
studies of chronic HBV patients with PNALT based on multiple
ALT readings found that HBeAg-negative carriers with low nor-
mal or high normal ALT values according to the traditional cut-
offs had similar severity of liver histological lesions and similarly
excellent long-term clinical outcomes [7,12,15,19,20]. Thus,
available data do not support the need for lowering the tradi-
tional cut-offs for the ULN of ALT values in patients with
HBeAg-negative chronic HBV infection.
Severe liver histological lesions were rare among HBeAg-neg-
ative patients with truly PNALT. In the four studies with good or
acceptable deﬁnitions of PNALT [7,8,11,12], more than a minimal
(always mild) inﬂammatory activity was detected in only 3% and
more than mild ﬁbrosis always with minimal inﬂammatory activ-
ity in only 5% (moderate ﬁbrosis: 4.5%, severe ﬁbrosis: 0.5%, cir-
rhosis: 0%) of 215 patients with serum HBV DNA 620,000 IU/
ml. The prevalence of mild inﬂammatory activity and moderate
ﬁbrosis was 7% and 10% among patients with HBV DNA levels
between 2000 and 20,000 IU/ml and 1.4% and 1% among those
with HBV DNA levels <2000 IU/ml. Similar mild histological ﬁnd-
ings in HBeAg-negative patients with HBV DNA 620,000 IU/mlormal ALT at baseline
one year
termination
ULN and 
,000 IU/ml
nd 
,000 IU/ml
mo, 
year and
y every year 
ALT >ULN and/or, 
HBV DNA >20,000 IU/ml and/or
liver stiffness >9 kPa
Liver biopsy
 mo, 
year and
y every year
ears
Persistently ALT <ULN and 
HBV DNA <2000 IU/ml
ALT every 6 mo*
HBeAg-negative chronic HBV infection and normal alanine aminotransferase
–4 months during the ﬁrst year. Patients with ALT persistently below ULN and HBV
⁄Periodical HBV DNA measurements may be also helpful, although the optimal
per limit of normal (<ULN) and HBV DNA 2000–20,000 IU/ml during the ﬁrst year
BV DNA and transient elastography monitoring during the second and third year
nths together with HBV DNA and transient elastography every year. Patients with
d for liver biopsy and treatment. The optimal liver stiffness cut-off for liver biopsy
HBV DNA <2000 IU/ml, should be monitored for life.
2 vol. 57 j 196–202
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have also been reported in three additional studies with good
deﬁnitions of PNALT, one from Italy [13], one from Taiwan [19]
and one from the USA [21]. These studies were not included in
this review because of the small number of patients who under-
went liver biopsy. In particular, minimal activity and no or mild
ﬁbrosis (grade 3–4 of 18 and stage 0–1 of 6 in the Ishak classiﬁ-
cation system) were found in all 10 HBeAg-negative Italian
patients with PNALT and HBV DNA levels persis-
tently <20,000 IU/ml and at least one HBV DNA level >2000 IU/
ml based on monthly ALT and HBV DNA determinations for 1 year
[13], while minimal activity was found in all 9 and mild ﬁbrosis
(grade 0–3 of 18 and stage 0–2 of 6 in the Ishak classiﬁcation sys-
tem) in 5 of 9 HBeAg-negative Taiwanese patients with PNALT
and HBV DNA persistently <20,000 IU/ml based on 6-monthly
ALT and 2-yearly HBV DNA determinations for P10 years [19].
These data suggest that histologically signiﬁcant liver disease is
rare in HBeAg-negative carriers with PNALT based on stringent
criteria and serum HBV DNA 620,000 IU/ml. Thus, such patients
can be considered as true inactive HBV carriers, who require nei-
ther liver biopsy nor immediate therapy but continued follow-up
(Fig. 1).
We acknowledge that a 10% prevalence of moderate ﬁbrosis in
HBeAg-negative patients with truly PNALT and HBV DNA 2000–
20,000 IU/ml is not negligible. However, this was always accom-
panied by minimal necroinﬂammatory activity and the beneﬁts
of treatment in these patients is unclear. Instead of recommend-
ing liver biopsy for all of these patients, further studies to identify
predictors of signiﬁcant liver histology (e.g. age, serial HBV DNA,
precore/core promoter HBV variant) to allow more targeted rec-
ommendation for liver biopsy in this group of patients are war-
ranted. Alternatively, these patients may be evaluated for liver
ﬁbrosis with non-invasive methods such as panels of serum
markers or liver stiffness measurement. Transient elastography
has been shown to correlate with ﬁbrosis in patients with chronic
hepatitis C [22], and also in patients with chronic hepatitis B [23–
25]. In chronic hepatitis B, cut-off liver stiffness values of 9–
10 kPa were reported to offer satisfactory predictive values for
the diagnosis of severe ﬁbrosis [23,24], even in patients with
transiently normal ALT [23]. The predictive value of elastography
may be lower in HBeAg-negative patients with truly PNALT and
low prevalence of severe ﬁbrosis or cirrhosis, but this is offset
by the lack of confounding by inﬂammation associated with high
ALT or ALT ﬂares [26], making liver stiffness measurements an
ideal tool to monitor disease progression in these patients.
Apart from the possibility of severe liver histological lesions,
arguments supporting treatment initiation in HBeAg-negative
patients with HBV DNA >2000 IU/ml regardless of ALT have been
based on concerns for increased risks of adverse long-term out-
comes. These concerns were mainly generated from the ﬁnding
of the population-based REVEAL study suggesting that HBeAg-
negative carriers with HBV DNA >2000 IU/ml have increased risk
of cirrhosis, HCC and liver-related mortality regardless of ALT
[27]. However, most of the analyses were based on baseline
HBV DNA and ALT levels or paired values (baseline and after
10 years follow-up). Thus, these data cannot be generalized to
HBeAg-negative patients with truly PNALT. Indeed, a long-term
study from Taiwan showed no evidence of disease progression
over 10 years in HBeAg-negative patients with truly PNALT and
HBV DNA levels up to 20,000 IU/ml [19].
Another argument for initiating therapy immediately in
patients with PNALT and HBV DNA levels >2000 IU/ml is thatJournal of Hepatology 201patients may not attend regular follow-up and would miss the
opportunity to initiate treatment at the right moment. However,
these same persons may not be adherent to long-term or lifelong
antiviral therapy. Adherence to nucleos(t)ide analogs for CHB in
clinical practice has been shown to be suboptimal and these
patients may not derive the desired beneﬁt of preventing disease
progression and may instead run the risk of antiviral drug resis-
tance [28].Summary and recommendations
In summary, we found very few studies with liver histology in an
adequate number of HBeAg-negative carriers with PNALT. Avail-
able data showed that in those studies with stringent deﬁnition
of PNALT, histologically signiﬁcant liver disease was rare, partic-
ularly in patients with serum HBV DNA <2000 IU/ml. Even among
HBeAg-negative carriers with serum HBV DNA between 2000 and
20,000 IU/ml, histologically signiﬁcant liver disease is uncommon
if they meet stringent criteria for PNALT. These data do not sup-
port routine liver biopsy or treatment for HBeAg-negative carri-
ers with PNALT and serum HBV DNA 2000–20,000 IU/ml.
Instead, we recommend lifelong monitoring with more frequent
testing during the ﬁrst 3 years. Patients with high baseline vire-
mia levels have higher risk of subsequent exacerbation [14,29].
These patients may beneﬁt from non-invasive assessment of liver
ﬁbrosis. Liver biopsy should be recommended if ALT becomes
abnormal, HBV DNA increases above 20,000 IU/ml or liver stiff-
ness exceeds 9 kPa on reliable measurements, although the most
appropriate liver stiffness cut-off needs further evaluation
(Fig. 1).
Key Points 
• Current guidelines favour liver biopsy in HBeAg negative 
chronic HBV patients with normal ALT and HBV DNA 
levels >2000 IU/ml
• However, the existing data show that histologically 
patients with persistently normal ALT based on stringent 
criteria (ALT determinations at least every 3-4 months 
≤20,000 IU/ml 
• Therefore, HBeAg-negative chronic HBV patients with 
persistently normal ALT can be considered as true 
inactive HBV carriers, even if they have serum HBV 
DNA levels between 2000-20,000 IU/ml. These patients 
require neither liver biopsy nor immediate therapy but 
continued follow-up
significant liver disease is rare in HBeAg-negative
during the first year of follow-up) and serum HBV DNAConﬂict of interest
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